TSX:ONC 0.75 CAD -0.03 -3.85% Volume: 174,842 July 7, 2015
NASDAQ:ONCY 0.59 USD -0.04 -6.41% Volume: 734,474 July 7, 2015

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

July 06, 2015 Oncolytics Biotech® Inc. Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic Cancer
June 15, 2015 Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 9th International Conference on Oncolytic Virus Therapeutics
June 12, 2015 Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders
Sign up to receive e-mail updates *